论文部分内容阅读
目的观察曲美他嗪(TMZ)治疗缺血性心肌病心功能不全的临床效果。方法选择我院收治的缺血性心肌病患者139例,随机分为曲美他嗪治疗组(TMZ组)89例和对照组50例,对照组予以常规药物治疗(血管紧张素转换酶抑制剂、β-受体阻滞剂、利尿剂,必要时加用硝酸类及地高辛等),TMZ组在此基础上加用TMZ20mg,每日3次口服,监测心率、血压、心功能情况,3个月后观察疗效。结果两组患者总有效率间差异有统计学意义(P<0.05)。两组患者治疗后LVEF、LVDD、LVSD间差异均有统计学意义(P<0.05)。结论缺血性心脏病心力衰竭患者在基础治疗的基础上,加用曲美他嗪可进一步改善心功能,能明显提高左心室射血分数,降低死亡率。
Objective To observe the clinical effect of trimetazidine (TMZ) in the treatment of heart failure of ischemic cardiomyopathy. Methods One hundred and ninety-three patients with ischemic cardiomyopathy admitted to our hospital were randomly divided into trimetazidine treatment group (TMZ group) and control group (n = 50). The control group was given conventional drug treatment (angiotensin converting enzyme inhibitor , Β-blockers, diuretics, nitric acid and digoxin if necessary). TMZ group was treated with TMZ 20 mg orally on the basis of this three times daily to monitor heart rate, blood pressure, heart function, After 3 months to observe the effect. Results The total effective rate between the two groups was statistically significant (P <0.05). The differences of LVEF, LVDD and LVSD between the two groups were statistically significant (P <0.05). Conclusion In patients with heart failure of ischemic heart disease, trimetazidine can be used to improve heart function, increase left ventricular ejection fraction, and reduce mortality.